Nagpur based Zim Laboratories Limited, a leading provider of new drug delivery systems, will be listing on Bombay Stock Exchange (BSE) Main Board on June 8 and will have a price discovery as per trading on the bourses. It is likely to fetch attractive returns for existing shareholders.
The book value price of Zim Labs, promoted by technocrate Dr Anwar Daud is Rs 160 per equity share. Daud and his family has 54 per cent stake in ZIM Labs and the private equity partner Ashmore Alchemy India Advisors has about 22 per cent. Rest is with minority shareholders.
Started in 1989 Zim Labs clocked Rs.275 crore revenue in fiscal 2018 followed by Rs.240 crore in fiscal 2017. Its profit after tax remained same at Rs.18 crore for FY 17 and FY 18.
Zim Labs is amongst a few companies globally to have developed and commercialized the oral film technology. Next month the company is going to launch multi-layer thin films that contain more than one API on a single thin strip.
Zim oral film technology (OTF) is patented as Thinoral with about 19 applied product/process patents for oral films globally. Of 53 patents filed by the company 24 belong to OTF. It has 198 registered formulations so far and applied for registration of 368 formulations. 159 formulations are under pipeline. It has 174 clients in 45 countries.
In FY 18, 38 per cent of the company's sales come from domestic market followed by 27 per cent from Asia (ex India), 20 per cent from Africa and 15 per cent from Middle East.
For OTF Zim Labs has received 24 DCGI product approvals and is awaiting 14 in India and 13 product approvals overseas. The company markets its product with some marquee brands like mankind, RPG, Sun Pharma, Delvin etc. It has developed 19 products and commercialized 13 of them.
In addition to OTF, Zim Labs has a category of product range-- pre formulation intermediaries and finished formulations.
Talking about company's growth strategy, Daud said “We enter into product co-development and supply partnerships with original product manufacturers/ marketing companies globally across delivery platforms and particularly for using Thinoral as alternate delivery platforms for extending product life cycle, specific customer targeting etc. We continue to foray into emerging and developed markets for supply of semi-finished formulations which are already being developed and marketed in rest of world market.”